2023 Annual Symposium For Evolving Therapies and Drug Development in Oncology: Targeted therapy, immunotherapy and beyond
This CME-accredited activity, “2023 Annual Symposium for Evolving Therapies and Drug Development in Oncology: Targeted therapy, immunotherapy and beyond”, is a two-day conference aimed at improving the knowledge and competence of academic and community oncology providers on the biomarker-guided treatment of cancer, and design and conduct of clinical trials in the era of novel therapies. The activity will use a mix of didactic lectures and panel discussions to highlight various aspects of precision oncology, including current challenges and opportunities in designing clinical trials in the era of novel therapies.
- Hematology/Oncology physicians
Upon successful completion of this educational activity, participants will be able to:
- Review recent updates in biomarker-guided treatment options for cancer patients.
- Review challenges and trends in drug development in the era of novel therapies.
- Outline the best practices for the conduct of Phase I clinical trials in the era of novel therapies.
- Identify the phase I clinical trials to match patients’ needs.
- Review the challenges and potential solutions for the diverse representation during drug development.
Conference Chairs: Nagla Abdel Karim, MD, PhD and Vivek Subbiah, MD
Honorary President: Alex Spira, MD, PhD, FACP
Day 1 - September 29, 2023
All times below are listed in Eastern Standard Time (EST).
03:00 PM - 04:00 PM - REGISTRATION & NETWORKING
04:00 PM - 04:05 PM - Welcome Note - Nagla Karim, MD
04:05 PM - 04:15 PM - Welcome Remarks - Binay Shah, MD
04:15 PM - 05:15 PM - SESSION 1: EVOLVING TARGETED THERAPIES
Session Chair: Raymond Wadlow, MD
04:15 PM - 04:30 PM - Tumor Agnostic Drug Development - Vivek Subbiah, MD
04:30 PM - 04:45 PM - Quality of Life as Measurement of Success for Clinical Trial Ishwaria Subbiah, MD
04:45 PM - 05:00 PM - Role of radiation therapy in the era of evolving systemic therapies - Salma Jabbour, MD
05:00 PM - 05:15 PM - Panel Discussion
Panelists: Safae Chouraichi, PharmD, BCOP, and Simona Armanca, PharmD, BCOP
05:15 PM - 06:30 PM - RECEPTION & NETWORKING
Day 2 - September 30, 2023
07:00 AM - 08:00 AM - REGISTRATION, BREAKFAST, & NETWORKING
08:00 - 08:15 AM - Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD
08:15 AM - 08:45 AM: SPECIAL SESSION 1 - UPDATE ON NCI-SPONSORED EARLY TRIAL PROGRAM
Session Chair: Matthew Reilley, MD
Speaker: Elad Sharon, MD, MPH
08:45 AM - 09:45 AM - SESSION 2 - EVOLVING IMMUNOTHERAPY LANDSCAPE
Session Chair: Matthew Reilley, MD
08:45 AM - 09:00 AM - Novel Immunotherapies: Beyond PD1/CTLA4 and LAG3 - Ludimila Cavalcante, MD
09:00 AM - 09:15 AM - Cellular Therapies in Phase I Programs - John Powderly, MD
09:15 AM - 09:45 AM - Panel Discussion
Panelist: Abdul Naqash, MD
09:45 AM - 10:00 AM - BREAK & EXHIBITS
10:00 AM - 10:30 AM: KEYNOTE LECTURE - THE FDA PERSPECTIVE ON EARLY PHASE PRE-MARKET DOSE OPTIMIZATION
Chair: John Deeken, MD
Speaker: Paul Kluetz, MD
10:30 AM - 11:00 AM: SPECIAL SESSION 2: MASTERING THE FIRST STEP: ESSENTIAL TOOLS FOR ASPIRING CLINICAL INVESTIGATORS IN PHASE I TRIALS
Moderators: Brian Van Tine, MD, PhD
Panelist: Raymond Wadlow, MD
11:00 AM - 12:00 PM - SESSION 3: REVOLUTIONIZING CLINICAL TRIALS WITH PRECISION ONCOLOGY: A GAME CHANGER IN CANCER TREATMENT
Session Chair: Amin Benyounes, MD
11:00 AM - 11:15 AM - The Perfect Match: Tailoring Personalized Therapies and Clinical Trials for Optimal Patient Outcomes - Michael Pishvaian, MD, PhD
11:15 AM - 11:30 AM - “LUNGMAP study; Connecting Patients with Cutting-Edge Therapies” - Jonathan Riess, MD
11:30 AM - 11:45 AM - The Role of Liquid Biopsy in Phase I Clinical Trials - Christian Rolfo, MD, PhD, MBA
11:45 AM - 12:00 PM - Molecular Tumor Board Cases & Panel Discussion
Panelist: Timothy Cannon, MD
12:00 PM - 12:45 PM - LUNCH & EXHIBITS
12:45 PM - 1:45 PM - SESSION 4: BREAKING BARRIERS: IMPACT OF DIVERSITY AND SPECIALIZED CARE OF RARE TUMORS
Session Chair: Stephen Liu, MD
12:45 PM - 01:00 PM - Increasing Diversity in Clinical Trials To Reduce Health Disparities: The Time is Now - Estelamari Rodriguez, MD, MPH
01:00 PM - 01:15 PM - Redefining Possibilities: Breaking Through the Horizons of Neuroendocrine Tumor Management - Jaydira Del Rivero, MD
01:15 PM - 01:30 PM - Cracking the KRAS Code: Novel Approaches to Targeting KRAS - Nagla Abdel Karim, MD, PhD
01:30 PM - 01:45 PM - Panel Discussion
Panelist: Teja Poosarla, MD
01:45 PM - 02:00 PM - BREAK & EXHIBITS
02:00 PM - 03:00 PM - SESSION 5: FUTURE OF DRUG DEVELOPMENT IN ONCOLOGY
Session Chair: Alex Spira, MD, PhD, FACP
02:00 PM - 02:10 PM - Precision medicine and the NCI Platform Studies - Alice Chen, MD, MPH
02:10 PM - 02:20 PM - ADC - Mohamad Salkeni, MD, FRCPC
02:20 PM - 02:30 PM - How Innovative Therapies are Breaking Barriers for Small Cell Lung Cancer - Asrar AlAhmadi, MD
02:30 PM - 03:00 PM - Panel Discussion and Q&As
Panelist: Triparna Sen, MS, PhD
03:00 PM - 03:30 PM: SPECIAL SESSION 3: LAYING THE FOUNDATION: "STEPS TO BUILD A SUCCESSFUL PHASE 1 PROGRAM"
Moderator: Bassel El-Rayes, MD
Panelists: Elad Sharon, MD, MPH John Powderly, MD, and Stéphanie Gaillard, MD, PhD
03:30 PM - 03:45 PM - BREAK
03:45 PM - 04:45 PM: SESSION 6 - BEYOND THE NUMBERS: NEW PERSPECTIVES ON MEASUREMENTS OF SUCCESS
Session Chair: Michael Winkler, MD
03:45 PM - 04:00 PM - Novel Therapies for Brain Metastases - Manmeet Ahluwalia, MD, MBA, FASCO
04:00 PM - 04:15 PM - Artificial Intelligence in Medicine - Heejong Kim, PhD
04:15 PM - 04:30 PM - Taking RECIST Measurements into Consideration - Daniel Margolis, MD
04:30 PM - 04:45 PM - Panel Discussion
Panelist: Tara Berman, MD
04:45 PM - 05:00 PM - Closing Remarks
PLEASE NOTE THIS IS JUST FOR ATTENDEES. If you are faculty (conference chairs, session chairs, speakers, case presenters), please complete the travel form emailed to you.
A limited number of rooms have been booked at the Hyatt Regency Dulles at the discounted rates listed below:
Please follow this link to make your room reservation -
Group code: G-EATH
Complimentary Airport Shuttle Service is available from 24/7 to and from Dulles International Airport. If you are flying into Dulles airport, a driver will pick you up outside Ground Transportation (lower level) at curb 2B or 2G. For airport pickup between Midnight and 6:00 AM, you will need to call and request pickup. The shuttle departs every 30 minutes, based on demand, from Hyatt Regency Dulles to Dulles Airport. For departures and arrivals between 11pm and 6:30am, please sign up at the Front Desk for shuttle service.
IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:
All conflict of interest has been identified and mitigated for individuals in control of contents.
PLANNING COMMITTEE DISCLOSURE STATEMENT:
None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.
Commerical Support Acknowledgment:
This activity is supported with an independent medical education grant from AstraZeneca Pharmaceuticals.
- 8.00 ABIM MOC IISuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 8.00 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 8.00 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.00 Contact Hours.
Physicians (non-industry) - $100
Non-physician HCP (non-industry) - $75
Industry representatives - $1250
Fellows/Residents - $0
POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE:
All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place.
The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference. The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees.
If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.
Violating this policy will result in a fine equivalent to a general display fee for that conference.
NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:
If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:
- If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
- If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event.
- If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event.
Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.
You may cancel your enrollment at any time. Cancellation fees apply as below:
- 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
- No refunds will be issued if registration is canceled after that date.
No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.